Paladin Wealth LLC Has $576,000 Stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Paladin Wealth LLC raised its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 9.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,457 shares of the medical equipment provider’s stock after purchasing an additional 472 shares during the quarter. Paladin Wealth LLC’s holdings in Zimmer Biomet were worth $576,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently modified their holdings of the company. Dunhill Financial LLC raised its position in Zimmer Biomet by 1,090.0% in the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after buying an additional 218 shares during the last quarter. Ashton Thomas Securities LLC purchased a new stake in shares of Zimmer Biomet in the third quarter valued at about $28,000. Brooklyn Investment Group bought a new position in shares of Zimmer Biomet during the third quarter valued at about $35,000. R Squared Ltd purchased a new position in Zimmer Biomet during the fourth quarter worth about $63,000. Finally, Mather Group LLC. grew its position in Zimmer Biomet by 100.9% in the 4th quarter. Mather Group LLC. now owns 661 shares of the medical equipment provider’s stock worth $70,000 after purchasing an additional 332 shares in the last quarter. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Stock Performance

Shares of ZBH opened at $100.40 on Tuesday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.70 and a current ratio of 1.91. The stock has a market capitalization of $19.99 billion, a price-to-earnings ratio of 22.56, a price-to-earnings-growth ratio of 1.83 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a 52-week low of $99.67 and a 52-week high of $133.90. The stock’s 50-day simple moving average is $107.34 and its 200 day simple moving average is $108.07.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, beating analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period last year, the company earned $2.20 earnings per share. Research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.25 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Monday, December 30th were paid a $0.24 dividend. The ex-dividend date was Monday, December 30th. This represents a $0.96 annualized dividend and a dividend yield of 0.96%. Zimmer Biomet’s payout ratio is presently 21.57%.

Analyst Ratings Changes

Several research firms have commented on ZBH. Royal Bank of Canada cut their target price on Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating on the stock in a research note on Friday. Barclays cut their price objective on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating on the stock in a research report on Monday. Oppenheimer decreased their target price on Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating for the company in a research report on Tuesday, October 15th. Wells Fargo & Company boosted their price target on shares of Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a report on Thursday, October 31st. Finally, Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a report on Friday. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $124.15.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.